Showing 3161-3170 of 4166 results for "".
- Nicox Appoints Robert N. Weinreb, MD, and Sanjay G. Asrani, MD, to its Glaucoma Clinical Advisory Boardhttps://modernod.com/news/nicox-appoints-robert-n-weinreb-md-and-sanjay-g-asrani-md-to-its-glaucoma-clinical-advisory-board/2479362/Nicox SA announced that two internationally recognized experts in glaucoma, Robert N. Weinreb, MD, Distinguished Professor and Chair, Ophthalmology and Director, Shiley Eye Institute, University of California San Diego; and Sanjay G. Asrani, MD, Professor of Ophthalmology, Duke University, will b
- Cognivue Initiates Nationwide Clinical Study to Assess Post-COVID-19 Syndrome (Long Haul Syndrome)https://modernod.com/news/cognivue-initiates-nationwide-clinical-study-to-assess-post-covid-19-syndrome-long-haul-syndrome/2479351/Neuroscience company Cognivue announced the initiation of
- Unity Biotechnology Announces Positive Data From Phase 1 Clinical Trial of UBX1325 in Patients With Advanced Vascular Eye Diseasehttps://modernod.com/news/unity-biotechnology-announces-positive-data-from-phase-1-clinical-trial-of-ubx1325-in-patients-with-advanced-vascular-eye-disease/2479342/Unity Biotechnology announced positive data from its phase 1 safety study of UBX1325 in patients with advanced disease from DME or wet AMD for whom anti-VEGF therapy was no longer considered beneficial. UBX1325, a small molecule inhibitor of Bcl-xL and the first senolytic therapeu
- Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathyhttps://modernod.com/news/ocuphire-initiates-zeta-1-phase-2-clinical-trial-investigating-apx3330-in-diabetic-retinopathy/2479060/Ocuphire Pharma announced that it has screened the first patient in ZETA-1, a phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR). Effects on diabetic macular edema will be explored as a secondary outcome. A number o
- Oasis Medical Launches Cyber Platform MY OASIS to Support Dry Eye Clinicshttps://modernod.com/news/oasis-medical-launches-cyber-platform-my-oasis-to-support-dry-eye-clinics/2479021/Oasis Medical is formally launching its new patented cyber platform MY OASIS at SECO International 2021, booth #722. MY OASIS is a cyber platform for eye care providers to build their brand as a dry eye resourc
- ProQR Announces Positive Results From Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trialshttps://modernod.com/news/proqr-announces-positive-results-from-clinical-trial-of-qr-421a-in-usher-syndrome-and-plans-to-start-pivotal-trials/2479006/ProQR Therapeutics announced results from a planned analysis of its phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. In the trial, QR-421a demonstrated benefit on multiple measures of v
- Bio-Tissue Receives FDA Clearance to Proceed with Clinical Study Using Investigational New Drug TTBT01https://modernod.com/news/bio-tissue-receives-fda-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-ttbt01/2478924/Bio-Tissue announced that its parent company TissueTech had received clearance from the FDA to proceed with a phase 2 study using morselized Cryopreserved Amniotic Membrane (CAM) and Cryopreserved Umbilical Cord (CUC) investigational new drug (IND) TTBT01. This clearance represents another milest
- Moderna’s Variant-Specific COVID-19 Vaccine Candidate Ready for Clinical Testinghttps://modernod.com/news/modernas-variant-specific-covid-19-vaccine-candidate-ready-for-clinical-testing/2478914/Moderna said that it has manufactured the initial batch of an updated version of its COVID-19 vaccine designed to better protect against the B.1.351 variant of SARS-CoV-2 first identified in South Africa. The company indicated late last month that it would be working on the variant-specific boost
- Ocular Therapeutix Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients With Glaucomahttps://modernod.com/news/ocular-therapeutix-presents-interim-topline-data-from-the-phase-1-clinical-trial-of-otx-tic-in-patients-with-glaucoma/2478784/Ocular Therapeutix announced plans to present data on OTX-TIC, a travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension, at the Glaucoma 360 New Horizons Forum being held virtually on January 30. As part of the event, Michael Goldstei
- Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Studyhttps://modernod.com/news/gemini-therapeutics-announces-gem103-meets-all-endpoints-in-phase-1-clinical-study/2478546/Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-